Picture of Scpharmaceuticals logo

SCPH — Scpharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

scPharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview

* scPharmaceuticals Inc  SCPH.OQ   SCPH.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
13 for the period ending September 30 2024
    * The Burlington Massachusetts-based  company is expected to
report a 184.5% increase in revenue to $10.801 million from $3.8
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for scPharmaceuticals Inc is
for a
loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for
scPharmaceuticals
Inc is 20.00​, above​ its last closing price of $4.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.42       -0.41      -0.44     Missed  -6.3
 Mar. 31 2024  -0.44       -0.44      -0.36     Beat    17.6
 Dec. 31 2023  -0.52       -0.42      -0.35     Beat    16.4​
 Sep. 30 2023  -0.37       -0.36      -0.41     Missed  -12.4
 ​​Jun.        -0.37       -0.37      -0.36     Beat    3.3
 30 2023                                                
 Mar. 31 2023  -0.39       -0.36      -0.30     Beat    17.8​
 Dec. 31 2022  -0.34       -0.39      -0.30     Beat    22.5
 Jan. 1 0001   -0.36       -0.38      -0.37     Beat    3.3
 This summary was machine generated November 12 at 03:51 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Scpharmaceuticals

See all news